Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00768391 · ClinicalTrials.gov registry record · Phase 1
Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00768391 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 20 participants.
The verdict
NCT00768391, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if IMC-3G3 is safe for patients, and also to determine the best dose of IMC-3G3 to give to patients.
Interventions
- BIOLOGICAL IMC-3G3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-12 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00768391
The ClinicalTrials.gov registry entry for NCT00768391 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IMC-3G3 is the first listed.
NCT00768391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00768391 about?
NCT00768391 is a clinical study titled "Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available". The purpose of this study is to determine if IMC-3G3 is safe for patients, and also to determine the best dose of IMC-3G3 to give to patients.
What is the current status of trial NCT00768391?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2006-12. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00768391?
The interventions under investigation include: IMC-3G3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00768391?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.